AstraZeneca will pay up to $420M for Moderna's mRNA technology

Moderna Therapeutics granted AstraZeneca five-year exclusive rights to use its messenger RNA technology to develop and market treatments for cancer and other serious diseases. Moderna will receive $240 million upfront and as much as $180 million in milestone fees plus sales royalties. The deal's initial payment is one of the biggest ever in a pharmaceutical licensing agreement that doesn't involve a clinical-stage drug.

View Full Article in:

New York Times (tiered subscription model), The · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN